Randomized, double‐blind, phase III study to evaluate the efficacy and safety of once‐daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes

This randomized, double‐blind, phase III study evaluated the efficacy and safety of once‐daily treatment with alogliptin (25 mg once daily), alone or with metformin hydrochloride (500 mg once daily or 250 mg twice daily), in Japanese patients with type 2 diabetes. The primary endpoint was change in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaku, Kohei, Sumino, Shuuji, Katou, Masafumi, Nishiyama, Yuya, Kinugawa, Yoshinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599944/
https://www.ncbi.nlm.nih.gov/pubmed/27891757
http://dx.doi.org/10.1111/dom.12837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599944/
https://www.ncbi.nlm.nih.gov/pubmed/27891757
http://dx.doi.org/10.1111/dom.12837

Ejemplares similares